Perifosine, also known as KRX-0401 or KRX0401, is a small molecule inhibitor that targets the phosphatidylinositol 3-kinase (PI3K) and Akt pathways, which are involved in regulating cell growth, proliferation, and survival. It has shown promise in preclinical studies for its potential to treat various types of cancer.
Chemical name: 3-(hexadecyloxy)-1,2-propanediyl 1-phosphate Molecular formula: C25H52O6P Formula weight: 476.65 g/mol CAS No: 157716-52-4
Top ten keywords and synonyms from Google search:
Health benefits of this product include its ability to inhibit the PI3K and Akt pathways, which play critical roles in regulating cell growth, proliferation, and survival. By blocking these pathways, Perifosine can potentially slow down or stop tumor growth in various types of cancer.
Potential effects of Perifosine include inhibition of tumor growth, induction of apoptosis in cancer cells, and modulation of immune response in various types of cancer. Preclinical studies have shown that Perifosine can enhance the effectiveness of other anticancer agents when used in combination therapy.
The mechanism of action for Perifosine involves inhibition of the PI3K and Akt pathways, which play critical roles in regulating cell growth, proliferation, and survival. By blocking these pathways, Perifosine can potentially slow down or stop tumor growth in various types of cancer.
Safety is an important consideration when using any therapeutic agent. Clinical studies have shown that Perifosine has a favorable safety profile, with no evidence of significant toxicity or serious adverse effects at therapeutic doses. However, as with any drug, careful monitoring and dose adjustment may be needed to minimize the risk of side effects.
Common side effects associated with Perifosine include nausea, vomiting, diarrhea, and fatigue. These side effects are generally mild and self-limiting, and most patients tolerate treatment well.
Dosing information for Perifosine varies depending on the patient's age, weight, and medical history. It is typically administered orally once daily, and the recommended dose range is 50-150 mg/day.
In conclusion, Perifosine is a promising small molecule inhibitor of the PI3K and Akt pathways, which play critical roles in regulating cell growth, proliferation, and survival. Its ability to modulate these pathways makes it a potentially powerful tool for treating various types of cancer. While it has a favorable safety profile, careful monitoring and dose adjustment may be necessary to minimize the risk of side effects. Further clinical studies are needed to determine the full therapeutic potential of this compound.
